Abstracts tagged "autoimmune diseases"

Abstract Number: 2559 • ACR Convergence 2023
Clinical Manifestations and Immunomodulatory Treatment in Patients with Relapsing Polychondritis
Roger Yang¹, Rennie Rhee², Kaitlin Quinn³, Naomi Amudala², Peter Grayson⁴, Peter Merkel², Marcela Ferrada⁵ and Shubhasree Banerjee², ¹University of Pennsylvania, Montréal, QC, Canada, ²University of Pennsylvania, Philadelphia, PA, ³National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Bethesda, MD, ⁴National Institutes of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), National Institutes of Health (NIH), Chevy Chase, MD, ⁵NIH, Bethesda, MD
Background/Purpose: Relapsing polychondritis (RP) is a rare systemic inflammatory disease without standard treatment guidelines. This study aims to investigate the clinical characteristics, current treatment approaches,…
Abstract Number: 0002 • ACR Convergence 2023
Population Pharmacokinetic and Pharmacodynamic Analyses of Obexelimab in Healthy Volunteers and in Patients with Rheumatoid Arthritis or IgG4-Related Diseases
Xiaodong Wang, Rachel Kirk, Simon Lowry and Hua Mu, Zenas BioPharma, Waltham, MA
Background/Purpose: Obexelimab is a novel bifunctional antibody that inhibits B-cells, CD19-expressing plasma cells, and plasmablast activity and has the potential to provide clinical benefits across…
Abstract Number: 0080 • ACR Convergence 2023
Pharmacological Inhibition of PRMT5 Demonstrates Broad Efficacy in Multiple Preclinical Models of Autoimmunity and Inflammation by Suppressing Th1, Th17 and TNF-Mediated Inflammatory Responses
Neha Bhagwat¹, Kumar Penmetsa², Matt Devalaraja³, Suzana Marusic⁴, Cornelia M. Weyand⁵, Shozo Ohtsuki⁶, Peggy Scherle¹ and Kris Vaddi¹, ¹Prelude Therapeutics, Inc, Wilmington, DE, ²Thermo Fisher Scientific, Philadelphia, PA, ³Nipuna Therapeutics, Waltham, MA, ⁴Hooke Laboratories LLC, Lawrence, MA, ⁵Mayo Clinic School of Medicine and Stanford University, Rochester, MN, ⁶Mayo Clinic College of Medicine and Science, Stanford University School of Medicine, Rochester, MN
Background/Purpose: Protein arginine methyltransferase 5 (PRMT5) is the major type II PRMT that catalyzes the formation of symmetrical dimethyl arginine (SDMA) on protein substrates and…
Abstract Number: 0198 • ACR Convergence 2023
Improving Vaccination Uptake of Herpes Zoster in Young Rheumatic Disease Patients Ages 18-49 Using Specialty Pharmacy Partnership
Stephen Lindsey¹, Brittany Hill², Sheela Sheth³ and Arya Loghmani², ¹LSU Health Science Center, New Orleans, LA, ²Louisiana State University, New Orleans, LA, ³Tulane University, New Orleans, LA
Background/Purpose: Herpes zoster (HZ), also known as shingles, causes an estimated one million cases annually in the United States. Many studies have shown that the…
Abstract Number: 0277 • ACR Convergence 2023
Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis
Julie Sarrand, Dorian Parisis, Muhammad Soyfoo and Paschalis Sidiras, Erasmus Hospital, Brussels, Belgium
Background/Purpose: This is the first systematic review and meta-analysis to examine the prevalence, the diagnostic and the prognostic value of anti-carbamylated protein (CarP) antibodies in…
Abstract Number: 0543 • ACR Convergence 2023
Sensitivity of the 2019 European Alliance of Associations for Rheumatology /American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus in a Population-based Cohort; A Study Set in Norway 2000-2015
Hilde Haukeland¹, Sigrid Reppe Moe¹, Cathrine Brunborg², Antonela Botea³, Nenad Damjanic⁴, Gro Wivestad⁵, Heidi Øvreås⁶, Thea Bøe⁷, Torhild Garen¹, Anniken Orre⁸, Helga Sanner⁹, Øyvind Molberg¹⁰ and Karoline Lerang⁹, ¹Oslo University Hospital, Department of Rheumatology, Oslo, Norway, ²Oslo Centre for Biostatistics and Epidemiology, Research Support Services, Oslo University Hospital - Rikshospitalet, Oslo, Norway, ³Betanien Hospital, Department of Rheumatology, Skien, Norway, ⁴Ostfold Hospital Trust, Department of Rheumatology,, Grålum, Norway, ⁵Hospital of Southern Norway Trust, Division of Rheumatology, Department of Medicine, Kristiansand, Norway, ⁶Lillehammer Hospital for Rheumatic Diseases, Department of Rheumatology, Lillehammer, Norway, ⁷Vestfold Hospital Trust, Department of Internal Medicine, Tønsberg, Norway, ⁸Vestre Viken Hospital Trust, Department of Rheumatology, Drammen, Norway, ⁹Oslo University Hospital, Department of Rheumatology, Nydalen, Norway, ¹⁰University of Oslo, Institute of Clinical Medicine, Oslo, Norway
Background/Purpose: To diagnose Systemic Lupus Erythematosus (SLE), one must understand the phenotype specter and interpret clinical, serological, radiological, and histopathological data, as well as exclude…
Abstract Number: 0734 • ACR Convergence 2023
Immune Isoform Atlas: Landscape of Alternative Splicing in Human Immune Cells and Involvement of Dysregulated Alternative Splicing in Autoimmune Diseases
Jun Inamo¹, Akari Suzuki², Mahoko Takahashi Ueda¹, Kensuke Yamaguchi¹, Hiroshi Nishida³, Katsuya Suzuki⁴, Yuko Kaneko⁵, Tsutomu Takeuchi⁶, Hiroaki Hatano⁷, Kazuyoshi Ishigaki⁸, Yasushi Ishihama³, Kazuhiko Yamamoto⁹ and Yuta Kochi¹, ¹Tokyo Medical and Dental University, Tokyo, Japan, ²RIKEN Center for Integrative Medical Science, Kanagawa, Japan, ³Kyoto University, Kyoto, Japan, ⁴Keio University, Shinjuku, Japan, ⁵Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Tokyo, Japan, ⁶Keio University School of Medicine and Saitama Medical University, Tokyo, Japan, ⁷Laboratory for Human Immunogenetics, RIKEN Center for Integrative Medical Sciences, Tokyo, Japan, ⁸RIKEN, Tokyo, Japan, ⁹Department of Allergy and Rheumatology, Graduate School of Medicine, The University of Tokyo and Laboratory for Autoimmune Diseases, Center for Integrative Medical Sciences, RIKEN, Yokohama, Japan
Background/Purpose: Alternative splicing events play a critical role in the immune system1,2 and one of major causal mechanisms for complex traits including immune-mediated diseases (IMDs),…
Abstract Number: 0959 • ACR Convergence 2023
Redirecting Macrophage Immunophenotype Attenuates Inflammation and Fibrotic Activation in Systemic Sclerosis
Heetaek Yang¹, Rajan Bhandari¹, Saemi Han², Chanhyuk Park¹, Chen-Yu Wang², Emily Morris¹, Michael Whitfield¹ and Patricia Pioli¹, ¹Geisel School of Medicine at Dartmouth, Hanover, NH, ²Dartmouth College, Hanover, NH
Background/Purpose: Systemic Sclerosis (SSc) is a rare autoimmune disease with multiple clinical and pathological manifestations including vascular involvement, immune activation, oxidative stress, and fibrosis. In…
Abstract Number: 1076 • ACR Convergence 2023
Rituximab-Associated Hypogammaglobulinemia in Patients with Rheumatic Diseases: A Multicenter Retrospective Observational Study
Olga Rusinovich¹, Enrique Calvo-Aranda², Claudia Maria Gomez², Patricio Cardoso Peñafiel², Pilar Navarro Alonso³, Miguel Cantalejo Moreira⁴, Alberto Diaz y Oca³, Pablo Navarro⁵, Maria Machattou⁵, Maria Alonso⁵, Carlota Navarro⁵, Carolina Merino⁵, Hilda Godoy⁶, Maria Carmen Barbadillo Mateos⁷, Carlos Isasi⁵, Maria Perez Ferro⁸, Jessica Polo⁹, Veronica Garcia¹⁰, Jose Luis Andreu-Sánchez¹¹, Jose Campos¹² and Jesus Sanz¹³, ¹Puerta de Hierro Majadahonda University Hospital, Boadilla del Monte, Spain, ²Hospital Universitario Infanta Leonor, Madrid, Spain, ³Fuenlabrada University Hospital, Madrid, Spain, ⁴Hospital Universitario de Fuenlabrada, Madrid, Spain, ⁵Puerta de Hierro Majadahonda University Hospital, Madrid, Spain, ⁶Hospital Universitario Puerta de Hierro, Madrid, Spain, ⁷Public, Madrid, Spain, ⁸Hospital Universitario Rey Juan Carlos, Madrid, Spain, ⁹Rey Juan Carlos University Hospital, Madrid, Spain, ¹⁰Ramon y Cajal University Hospital, Madrid, Spain, ¹¹Rheumatology, Hospital Universitario Puerta de Hierro, Majadahonda, Spain, ¹²Hospital Universitario Puerta de Hierro Majadahonda, Majadahonda, Spain, ¹³Hospital Universitario Puerta de Hierro, Majadahonda, Spain
Background/Purpose: Rituximab (RTX) is a murine/human chimeric monoclonal antibody directed against the CD20 receptor expressed on pre-B and mature B cells. Rituximab is used effectively…
Abstract Number: 1322 • ACR Convergence 2023
Efzofitimod, a First-in Class NRP2-targeting Immunomodulator, Ameliorates Rheumatoid Arthritis and Associated Lung Fibrosis in Preclinical Models
Christoph Burkart, Clara Polizzi, Lisa Eide, Max Pastenes, David Siefker and Leslie Nangle, aTyr Pharma, San Diego, CA
Background/Purpose: Efzofitimod, a novel immunomodulator, has shown clinical proof-of-concept in a Phase 1b/2a clinical trial in patients with pulmonary sarcoidosis and is currently enrolling a…
Abstract Number: 1585 • ACR Convergence 2023
Defining Neutrophil-Mediated Renal Damage Triggered by Ultraviolet (UV) Skin Exposure
Angelique Cortez¹, Lindsay Mendyka², Fred Kolling³, Michael Whitfield¹ and Sladjana Skopelja-Gardner⁴, ¹Dartmouth College, Hanover, NH, ²Dartmouth Hitchcock, Lebanon, NH, ³Geisel School of Medicine at Dartmouth, Hanover, NH, ⁴Dartmouth-Hitchcock, Lebanon, NH
Background/Purpose: Lupus (SLE) is one of the leading causes of death in young women in the United States. Roughly ~80% of SLE patients experience sensitivity…
Abstract Number: 1735 • ACR Convergence 2023
An Unorthodox HLA-DRhiCD15+ ‘Hybrid’ Population in Rheumatoid Arthritis Characterized Using Spectral Cytometry
Christian Geier¹, Haani Qudsi², Jihad BenGabr¹, Robert Winchester³ and Andras Perl⁴, ¹SUNY Upstate Medical University, Syracuse, NY, ²Norton College of Medicine, SUNY Upstate Medical University, Syracuse, NY, ³Columbia University, New York, NY, ⁴SUNY, Syracuse, NY
Background/Purpose: A variant of HLA-DR confers the strongest genetic risk for rheumatoid arthritis (RA) suggesting that DRhi cells are important in RA. We previously found…
Abstract Number: 1923 • ACR Convergence 2023
Prevalence and Patterns of Comorbidities in Different Rheumatic Diseases: A Study from Tertiary Healthcare Centre
Smruti Ramteke¹, sanjay Ramteke² and Sandeep Yadav³, ¹Arthritis Clinic, Jasleen Hospital, Nagpur, India, ²Government Super Speciality Hospital Nagpur, Nagpur, India, ³P D Hinduja national Hospital and medical Research centre, Mumbai, India
Background/Purpose: The prevalence of comorbidities in rheumatic diseases may vary by disease and geographic region. This study aimed to investigate the comorbidities associated with rheumatoid…
Abstract Number: 2056 • ACR Convergence 2023
Pediatric Acute-onset Neuropsychiatric Syndrome: Markers of Inflammation/autoimmunity at Clinical Presentation and Eventual Development of Arthritis and Other Autoimmune Diseases
Meiqian Ma¹, Erin Masteron² and Jennifer Frankovich¹, ¹Stanford University School of Medicine, Palo Alto, CA, ²University of Washington School of Public Health, Seattle, WA
Background/Purpose: Certain psychiatric conditions are associated with systemic inflammatory processes. We aimed to evaluate whether a pediatric condition characterized by a sudden onset of severe…
Abstract Number: 2358 • ACR Convergence 2023
Neutrophil Extracellular Traps Induce Endothelial-to-Mesenchymal Transition and Associate with Vascular Complications in Scleroderma
Ramadan Ali¹, Wenying Liang¹, Claire Shiple¹, Rosemary Gedert², Suiyuan Huang¹, Cyrus Sarosh¹, Eliza Pei-Suen Tsou¹, Dinesh Khanna¹ and Jason Knight¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan, Onsted, MI
Background/Purpose: Systemic sclerosis (SSc, also known as scleroderma) is a disease characterized by fibrosis, autoimmunity, and vasculopathy. Many devastating complications such as digital ulcerations, scleroderma…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].